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Introduction
Duchenne muscular dystrophy (DMD), defined more 
than 150 years ago, is the most widespread type of muscular 
dystrophy in children, affecting 1:3500/5000 liveborn boys 
[1, 2]. DMD belongs to the group of dystrophinopathies, 
affected by genetic mutations in the gene that codes for 
dystrophin and defined by variable degrees of skeletal and 
cardiac muscle impairment. Typically, DMD is the most se-
vere form while Becker muscular dystrophy (BMD) is more 
benign form along with the X-linked DCM (XL-DCM) and 
the cardiomyopathy of DMD/BMD carriers [3-5].
Mutations linked to the dystrophin gene occur in the 
short arm of the X chromosome (Xp21.1), which describes 
the largest known gene, composed of 79 exons [6, 7]. Mu-
tations causing a shift in the open reading frame occur in 
the lack of dystrophin, leading to the DMD phenotype. 
X-linked recessive inheritance model is typical for this dis-
ease; a mother-carrier has a 50% chance of transmitting it 
to her boys. Although most DMD mutations are inherited, 




Cardiomyopathy secondary to Duchenne muscular dystrophy in children
*1,2Iulia Rodoman*, 1,2Ina Palii, 1Victoria Sacara, 1,2Sergiu gladun
1Cardiology Unit, Institute of Mother and Child, Chisinau, the Republic of Moldova
2Department of Pediatrics, Nicolae Testemitanu State University of Medicine and Pharmacy
Chisinau, the Republic of Moldova
Authors’ ORCID iDs, academic degrees, and contributions are available at the end of the article
*Corresponding author: iulia.rodoman@gmail.com
Manuscript received January 11, 2021; revised manuscript April 12, 2021; published online April 28, 2021
Abstract
Background: Cardiomyopathy (CM) associated with Duchenne muscular dystrophy (DMD) is a commonly recognized appearance of this neuromuscular 
disease, significantly increased morbidity and mortality, as well as the necessity for cardiological management. CM in DMD is defined by left ventricular 
(LV) systolic dysfunction and both atrial and ventricular dysrhythmias and is associated with higher mortality than other cases of pediatric dilated CMs. 
Notwithstanding the high rate of cardiac involvement, patients are usually asymptomatic despite significant LV dysfunction, because of likely poor mobility 
that masks the usual heart failure (HF) symptoms. Also, imagistic predictors are provided to be very helpful in defining early LV dysfunction, especially 
electrocardiogram and cardiac imaging (transthoracic echocardiography, speckle-tracking, cardiac magnetic resonance) are used to detect the onset and 
progression of dilated cardiomyopathy (DCM) in DMD. 
Conclusions: As most DMD patients are asymptomatic for a long time of their life, so identifying predictors of HF is crucial to support these patients. 
Ventricular dysfunction based on the ejection fraction (EF) measurement helps to choose therapy. In the case of early DCM (LVEF≥50%) the great 
purpose is to prevent ventricular dysfunction incipience with first-line HF therapy with Angiotensin-converting-enzyme inhibitors (ACE-I) or angiotensin 
receptor blockers (ARBs). Current guidelines recommend the use of conventional HF medication in case of disease progression and DCM with Mid-
Range Reduction of LV EF (40-49%). The therapeutic approach for patients with DCM and severe ventricular dysfunction (<40%) has been studied less 
profoundly and contemporary guidelines recommend all drugs used for HF treatment. 
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The major presenting manifestation of DMD is skele-
tal muscle weakness. Notwithstanding a family history, 
this diagnostic should be suspected in boys manifesting 
gait disturbances occurring between two and five years of 
age, followed by proximal weakness, delayed psychomo-
tor development, calf hypertrophy, and high levels of liver 
transaminases. The primary screening includes the dosage 
of the enzyme creatine phosphokinase (CPK), which is usu-
ally high (> 2000 U/L). Confirming tests range according to 
availability, but they embrace genetic tests that show specific 
gene mutations (deletions, duplications, point mutations) or 
muscle biopsy revealing the deficiency of dystrophin [9]. 
However, the heart muscle is affected by multiple mus-
cular dystrophies. Cardiomyopathy associated with DMD is 
a commonly recognized appearance of this neuromuscular 
disease, significantly increased morbidity and mortality, as 
well as the necessity for cardiological management [10]. 
Progressive muscular damage leads to increasing muscu-
lar weakness and motor dysfunction, motor development 
delays, and impairment in respiratory and cardiovascular 
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function. Until recently, respiratory failure secondary to 
neuromuscular dysfunction was the most common rea-
son for death, but at the moment dilated cardiomyopathy 
(DCM), arrhythmias, and congestive heart failure (HF) 
represent the most life-limiting heart condition in DMD [9, 
11, 12]. Nevertheless, the development of respiratory care 
across the last few years has made cardiomyopathy (CM) 
an increasing cause of morbidity and mortality in DMD pa-
tients [13-15]. 
DMD DCM is described by left ventricular (LV) systolic 
dysfunction and arrhythmias, which are allied with higher 
mortality than other cases of pediatric dilated CMs. Quick 
detection and management are associated with postponed 
progression of LV dysfunction and advance in results. How-
ever, DMD CM remains underrecognized and undertreated 
broadly because the symptoms of heart failure in these pa-
tients are frequently neglected and not clinically apparent 
[16].
Epidemiology
The prevalence of DMD in the USA, Australia, England, 
and Canada is estimated to be 1 per 3500 to 50000 male 
births [17]. But according to the data of Sacară et al. the 
frequency of DMD/BMD is 9.13:100000 for the Republic of 
Moldova [18, 19]. The DMD onset mean age is 3–5 years 
and patients usually remain in the non-ambulatory stage till 
the age of 10–12 [15, 16]. The symptomatic HF incidence is 
rare early in childhood but increases at the age 10-20. Pro-
spective studies have estimated the prevalence of DCM and 
noted it in the third of the patients under 14 years, half in 
those who were 18 years old, and almost all patients who 
were older than 18 years [14-17]. There have also been 
records of patients with X-linked DCM with low clinical 
evidence of skeletal muscle disease due to compensatory 
upregulation of the brain (B) isoform in skeletal muscle but 
not cardiac myocytes, although this is a unique phenotype 
[12, 20]. Female carriers have a chance to be influenced by 
this disease, although men manifest cardiac dysfunction at 
a significantly more youthful age than women. The awaited 
life prognosis with modern therapies, such as assisted venti-
lation is 25–30 years of age [15, 16].
Pathophysiology of DMD DCM
DMD is caused by mutations in the dystrophin gene 
that result in the reduction or absence of the sarcolemmal 
protein dystrophin, a protein that plays a fundamental role 
in the cytoskeleton of muscle cells by attaching intracellular 
structures with the extracellular matrix [21]. Some patho-
mechanisms have described cellular impairment initially 
caused by the absence of dystrophin, in both skeletal and 
cardiac muscles. 
Dystrophin is located on the cytoplasmic side of cardiac 
and skeletal muscle sarcolemma and contributes to struc-
tural maintenance. It is a component of a larger glycoprotein 
complex and is also involved in cellular regulation and sig-
nal transduction. In cardiac muscle, the lack of dystrophin 
ends in instability and progressive degeneration of the mus-
cle fibers through membrane vulnerability with continuous 
muscle compressions [22, 23]. 
Ordinarily, dystrophin presents structural maintenance 
for the myocyte and sarcolemmal membrane by its binding 
of actin at the C amino-terminus with the dystrophin-as-
sociated protein complex and sarcolemma at the carboxyl-
terminus and the extracellular matrix of muscle [6, 24]. 
Dystrophin is additionally existing in the T-tubular 
membranes of cardiac myocytes and is implicated in the 
supporting of membrane stability and transduction of me-
chanical energy from the sarcomeres to the extracellular 
matrix. The loss of the dystrophin guides to an extreme vul-
nerability of the cellular membranes; cellular stress could be 
immediately interfered with by the absence of dystrophin, 
or obliquely via intracellular Ca2+ overload or oxidative 
stress. 
Abnormal calcium handling due to the lack of dys-
trophin is believed to perform a significant function in the 
pathogenesis. Damage of cell membrane integrity and for-
mation of breaks may result in high calcium levels in muscle 
fibers. Stretch-activated channels may perform abnormally 
leading to increased calcium entry. Elevated cytoplasmic 
calcium may activate proteases, such as calpain and increase 
the generation of reactive oxygen varieties producing injury 
to cellular proteins and membranes [25, 26]. Reactive oxy-
gen kinds activate NF-KB pathways directing to increased 
pro-inflammatory cytokines. Inflammation may be harm-
ful, promoting additional muscle degradation and necrosis 
[25, 26].
The generation of these damaging cellular pathways and 
Ca2+ pathways manage to dystrophic DCM [27]. As muscle 
syndrome advances, skeletal and cardiac myocytes necro-
tize, and mechanisms of repair are also not enough, with 
consistent gradual replacement by fibrofatty tissue [28]. 
DMD DCM is marked by a weaker LV wall and its pro-
gressive dilatation, reflecting the continuing myocyte dam-
age [9, 29]. In particular, the constant mechanical stress 
manages to apoptosis and fibrotic replacement and scarring 
that progresses from the epicardium to the endocardium, 
starting at behind the posterior region and mitral valve ap-
paratus. This scarring develops downward progressively via 
the apex and around the heart, finally attending to DCM 
[30-32].
Disease predictors
Contemporary 2018 DMD Care Guidelines estimated 
that regular cardiac follow-up is crucial for care [16]. From 
the time of the final diagnosis, all energy should be direct-
ed to detect the early incipience and the progression of the 
DCM, which is very challenging.
Notwithstanding the high rate of cardiac involvement, 
patients are usually asymptomatic despite significant LV 
dysfunction, because of likely poor mobility that masks the 
usual HF symptoms. Dyspnea on exertion or decreased ex-
ercise capacity goes unnoticed due to concomitant skeletal 
muscle weakness. Orthopnea and paroxysmal nocturnal 
dyspnea can be missed due to the use of nocturnal non-in-
vasive mechanical ventilation for rest [15, 16, 33].
Early identification is so important for treatment, condi-
tioning the life expectancy. In the non-ambulatory stage, an 
72
ReVIeW ARTIcLeI. Rodoman et al. Moldovan Medical Journal. June 2021;64(2):70-78
asymptomatic patient’s continuing check-up is necessary to 
determine the progress of the disease. Clinical examination 
remains difficult because of low BP rates, cool extremities 
due to reduced skeletal muscle mass. Therefore, these clini-
cal features require a multidisciplinary evaluation to distin-
guish ongoing of the cardiac process.
However, enhanced survival of patients with DMD has 
contributed to an increase in overall the incidence and prev-
alence of CM [15]. Early detection is a key in preventative 
treatments that can delay the progressive deterioration in 
cardiac function and the start of overt HF symptoms.
Several biomarkers are currently used in the diagnosis 
and monitoring of cardiac disease. One such biomarker is 
cardiac troponin I, which is discharging during myocar-
dial cell injury and classically utilized for the diagnosis and 
evaluation of myocardial infarctions. Also, serum biomar-
kers are provided to be very helpful to define HF and are 
currently used to evaluate the functional state in adult and 
pediatric patients.
Electrocardiogram and cardiac imaging are also routine-
ly used to detect the onset of DCM and its progression [29]. 
These non-invasive tests provide useful information about 
the ventricular function, both systolic and diastolic ones. 
Cardiomyopathy in DMD is described by progressive 
fibrosis in LV finalizing into its dysfunction and dilatation 
[9]. Echocardiographic precursors of cardiac dysfunction 
appear in 10-20 years of life and are almost completely 
present in all adults [33]. So, the investigation into recog-
nizing additional, potentially modifiable predictors for 
CM progression is limited. Studies in mdx mice, a mouse 
model of DMD, show that dystrophin-lacking myocardium 
is more exposed to pressure overload of the LV than normal 
one [34]. Increased LV afterload may pose the already weak 
myocardium of DMD patients at risk for accelerated myo-
cardial dysfunction. LV afterload is influenced by hyperten-
sion, obesity, and aortic stiffness [35]. 
DMD DCM and other comorbidities
Some studies have distributed cross-sectional data on 
the prevalence of hypertension in DMD patients [36-38]. 
Ricotti et al. found hypertension in 5% of the patients aged 
3–15 years on steroids while in a study by Braat et al. 45% 
of the patients had hypertension [37, 38]. Wong et al. re-
ported that 25.5% of patients on daily steroids aged 10–13 
years had systolic hypertension [36]. In patients aged 13–16 
years, they reported systolic hypertension in 10.3% of pa-
tients. One study described a correlation between low blood 
pressure (BP) ranges and younger age in DMD with His-
panic origin as an involving predictor [39].
Obesity is commonly found in DMD due to corticos-
teroids using and low mobility [40]. Prevalence of obesity 
has been described in up to 73% DMD patients on steroid 
treatment <13 years and higher body-mass index (BMI) was 
correlated with longer duration and greater cumulative dose 
in ambulant DMD patients utilizing prednisone [41, 42]. In-
creased BP is a well-known side outcome of corticosteroids 
[43]. But its utilization has led to the ambulant stage prolon-
gation in DMD by almost 3 years [44]. It has also been cor-
related with a delayed onset of DMD-related cardiomyopa-
thy [45, 46]. Corticosteroid treatment is thus an essential 
part of the standards of care in DMD and is prescribed from 
the age of 4 to 5 years onward. Extensive research analyzing 
BP values in DMD patients with and without steroids will 
therefore not be feasible, and the high percentage of patients 
on steroids in this study may well be the cause that steroid 
use was not an objective factor in the linear mixed model. 
In  N.M. van de Velde et al.  study increased BMI, but 
not systolic BP was linked to early myocardial deformation 
defined by peak systolic global longitudinal strain (GLS) in 
young DMD patients < 11 years of age. The results of this 
study propose that factors influencing afterloads, such as 
increased BP and BMI, may play an important role in the 
degeneration of cardiac function in DMD [47]. 
genotype-phenotype correlations in DCM-DMD
The dystrophin gene is the largest gene identified in 
humans, and its complexity and correlation to phenotype 
remain to be analyzed [48]. Inheritance is in an X-linked 
recessive manner. Genetic mutations are generally out of the 
frame and cover duplications, deletions, frameshift (non-
sense and splice), missense, and premature stop codon [49]. 
Numerous attempts were tried to order DMD patients based 
on their genotype. Where the mutation happens within the 
gene has some correlation for cognition (i. e. mutations up-
stream of exon 30 correlates with spared cognition), but not 
motor function [50].
There are limited data correlations in genetic mutations 
and CM in DMD. It is still an open question whether vari-
ations in genotype indicate myocardial dystrophin expres-
sion, and consequently what impact they will produce on 
cardiac function. Therefore, Jefferies et al.’s study proved 
that mutations in exons 12 and 14 - 17 were associated with 
cardiomyopathy but mutations in exons 51 and 52 appeared 
to be protective against cardiac involvement [51]. However, 
other researches using different techniques have been un-
certain [49]. 
Biomarkers in DMD DCM
Cardiac troponin may be a predictor of CM secondary to 
DMD. Troponin I is released in the circumstances of DMD 
heart disease, likely as a consequence of membrane integrity 
loss rather than a primary ischemic etiology, but there are 
contradictory results about their diagnostic and prognostic 
involvements in the DMD DCM [52-54].
High cardiac troponin levels are strongly correlated with 
left ventricular dysfunction and may indicate the progres-
sion of the cardiomyopathy when acute chest pain is present 
[55]. It also seems to correspond with the conclusion of my-
ocardial fibrosis on cardiac MRI [56].
Recently, one study revealed that troponin I levels were 
significantly elevated in patients with moderate late gado-
linium enhancement (LGE) related to no LGE and constant 
over all ages, and it is interesting, that absence of positive 
correlation among mild-to-severe LGE and troponin is 
presumably because of a reduced dystrophin amount at ad-
vanced disease stages when most of the heart muscle has 
already been replaced by conjunctive tissue. Therefore, tro-
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ponin I could provide valuable data to control patients in 
the clinical practice, and extra studies are needed [56]. 
Based on the above, troponin can be a valuable mini-
mally invasive outcome marker to find early myocardial 
disease implications and understand the origin of damage 
in DMD CM. 
High left atrial pressure as a consequence of pulmonary 
hypertension and LV dysfunction induced by respiratory 
muscles impairment are supposed to be implicated in ap-
pearing of high levels of plasma natriuretic peptide in DMD. 
In patients with a non-ambulatory stage of DMD was ob-
served mild or marked elevation of alpha-ANP levels being 
a sign of a lower prognosis and may be a useful predictor 
for disease management [57]. Villa et al. in their study re-
ported a meaningful association among cystatin C, eGFR, 
and heart muscle dysfunction, contributing to the newest 
predictor to confirm cardiorenal syndrome in children with 
DMD [58]. 
In Carol A. Wittlieb-Weber et al. study, BNP levels 
measured before dying or research end were significantly 
higher for those patients who died compared to those liv-
ing at research finish [59]. These conclusions are compat-
ible in Cheeran et al. study, who investigated a cohort of 43 
DMD patients with CM, and discovered predictors in com-
paring the non-living to the living cohorts including lower 
BMI, maximum inspiratory pressures, and cardiac serum 
biomarkers [60]. 
Imagistic predictors in DMD DCM
Electrocardiographic abnormalities
Electrocardiographic (ECG) follow-up is obligatory and 
valuable for the cardiological evaluation of DMD patients. 
Electrocardiographic irregularities commonly found in 
patients with DMD can correspond to fibrotic alterations 
seen on pathology expertise [16, 61]. But, according to 
some reports, the ECG frequently does not correlate with 
CM development [62]. In the process of LV function fai-
ling, it is possible to find more frequently sinus tachycardia, 
supraventricular and ventricular arrhythmias. In Fayssoil et 
al. study bundle branch block is a significant predictor for 
cardiac situations, while patients with low dystrophin level 
show an increased incidence of cardiac events [63]. 
There can be different changes on a traditional ECG: si-
nus tachycardia, short PR, high R waves in right precordial 
derivations, right ventricular hypertrophy, and Q waves in 
left lateral and precordial leads (D1, aVL, V5, V6), narrow 
and deep Q waves. The sinus tachycardia phenomenon is 
the most described finding in DMD. It is also essential to 
remark that RSr’ pattern and high R waves in V1 can be 
normal in childhood, with no association with heart di-
sease [64]. Also, there are some data about the correlation 
between the left bundle branch block and mortality in adult 
patients on mechanical ventilation [63]. Significant arrhyth-
mias in the 24-h Holter ECG, especially atrial and ventricu-
lar tachycardias, were uncommon findings in patients with 
ejection fraction (EF) more than 35% and had low clinical 
applicability in patients with preserved EF [65]. 
Transthoracic Echocardiography/ Speckle-Tracking 
Echocardiography performs the main function in LV 
dysfunction identification and also dynamic evaluation is 
required. According to the literature, local anomalies of LV 
function may be resolved by other imaging investigations, 
such as speckle tracking echocardiography (STE) or cardi-
ac magnetic resonance (CMR) [66]. Dilated LV is assessed 
via standard deviations, estimated with Z-scores compared 
with age, BMI in DMD patients. LV dysfunction is consid-
ered lower than 55%, and fractional shortening (FS) lower 
than 28% [67, 68].
Correlation of 2D and 3D echo techniques for LV end-
diastolic volume (LVEDV) and left ventricular end-systolic 
volume (LVESV) was significantly positive, but 3D LVEDV 
and LVESV were lower in comparison with 2D outcomes; 
while, LV EF estimation was similar in two methods [69]. 
According to some reports, FS is rated the best evaluator 
of LV systolic function, because of its independence of age 
and magnitude of measures [70]. In the matter of diasto-
lic function, in DMD patients can be found the follouing 
echocardiographic abnormalities: high mitral A-wave ve-
locities and lower E/A ratio, lower DTI lateral peak E-wave 
velocities [70]. 
Another predictor of LV dysfunction in DMD patients 
is the myocardial performance index (MPI) gained by using 
pulse-wave Doppler and Doppler tissue imaging. Based on 
the intraclass coefficient correlation, MPI obtained with 
Doppler tissue imaging was more reproducible. 
STE is a modern technique capable to determine sub-
clinical LV dysfunction before the overt LV EF reduction, 
that is recently frequently used in DMD patients. The myo-
cardial strain is irregular in almost 50% of DMD patients, 
showing lower GLS values compared to the control group 
notwithstanding a normal LV EF [71, 72]. Furthermore, 
a reduction of 0.34%/year of GLS value in DMD patients 
according to age has been described [73]. In this study, in 
patients with DMD were observed differences in longitudi-
nal (3.6%), radial (9%), and circumferential (3.8%) strains 
compared to healthy controls, with significantly lower va-
lues in the inferolateral and anterolateral mid-basal seg-
ments [73]. 
Another retrospective studies previously described cir-
cumferential and longitudinal strains in DMD patients with 
a greater difference for these indicators [67, 70]. However, 
STE analysis is often restricted in DMD because the 
echocardiographic picture quality is low in these patients 
due to chest malformations, lung hyperinflation, and limi-
ted mobility and decays by 2.5% for each 1-year in plus in 
age [66]. There was a suboptimal echocardiographic quality, 
defined as more than 30% of segments incompletely visua-
lized, observed in 50% of 13-year-old DMD patients and 
78% of 15-year-old patients [66]. 
Surely, LV EF, obtained by echocardiography, has been 
demonstrated to associate with CMR, while 2-D FS and 
5/6 area length LV EF correlated strongly with CMR LV EF 
[26, 67].
Right ventricular (RV) function is frequently protected 
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in DMD patients, accompanying by LV dysfunction, pre-
sumably because of the decreased afterload of respiratory 
changes. In Mehmood et al. study normal RV values were 
reported in subjects with severe LV dysfunction, and only in 
few cases there have been described advanced RV dysfunc-
tion [74].
Therapeutic management for DCM-DMD
Usually, HF changes the definition to the manifestation 
of clinical symptoms. Most DMD patients are asymptomatic 
for a long time of their life, so identifying predictors of HF 
is essential to maintain these patients. Ventricular dysfunc-
tion based on the EF measurement helps to provide therapy. 
DMD DCM can be classified as normal LV EF (≥50%), mid-
range (40-49%), and reduced LV EF (<40). In the following 
section, all cardiovascular drug therapies are described ac-
cording to LV EF [75].
Early DCM (LVEF≥50%)
The great purpose is to prevent the ventricular dys-
function incipience at this stage of the disease. Because of 
specific therapy absence for HF in DMD, 2018 DMD Care 
Guidelines recommend traditional first-line HF therapy 
with angiotensin-converting-enzyme inhibitors (ACE-I) or 
angiotensin receptor blockers (ARBs) [16].
In 2005, Duboc D. reported results of five-year study for 
the prophylactic use of perindopril in DMD patients. This 
research had to estimate the perindopril effect on LV dys-
function history. In this study, 57 children aged 9.5 to 13 
years with a normal cardiac test and LV EF of more than 
55%, were randomized to perindopril 2–4 mg versus the pla-
cebo group. The chi-squared analysis revealed a significant 
advantage for patients treated to prevent the progression of 
DCM, described as the decrease of LV EF under 45%. After 
this study, ACEi has been initiated to be prescribed in pro-
phylactic scopes [76].
DMD DCM with Mid-Range Reduction of LV EF (40-
49%)
Several kinds of research have been labeled for DMD 
patients with moderate systolic LV dysfunction and showed 
some beneficial effects to preserve its appearance. Current 
guidelines recommend the use of conventional HF medica-
tion in case of disease progression. In 2013, Allen H. com-
pared the outcomes of lisinopril with losartan in a rand-
omized, double-blind, controlled trial of 22 DMD patients, 
that showed no difference between lisinopril and losartan in 
controlling ventricular function [77].
The cardioprotective impact of eplerenone in combi-
nation with ACE-I or ARB was assessed by CMR after 12 
months in 42 DMD patients. In this multicenter, rand-
omized, placebo-controlled trial, Raman S. et al. revealed 
that eplerenone decreased the decline of magnetic reso-
nance assessed LV circumferential strain and LV EF at 12 
months when matched to the placebo group [78]. Also, Ra-
man S. et al. showed that early MRA therapy is effective and 
safe in a genetic disease with high cardiomyopathy risk [79].
Accordingly, at the ambulatory stage of the disease, be-
fore any clinical overt DCM, the preventive use of perindo-
pril for cardioprotection is started extensively in the clini-
cal practice and endorsed by current indication although 
biological consequences are still unclear. When the DCM 
is detectable even in case of a mild reduction of EF (>45% 
LVEF), fosinopril or losartan with the combination of MRA 
can increase ventricular function.
Also, beta blockers (BB) have been tested. In 22 pa-
tients carvedilol was administered and progressively in-
creased over 8 weeks. This therapy modestly improved 
cardiac CMR-derived measured EF (41% +/− 8.3% to 43% 
+/− 8%; p < 0.02), as well as the MPI (0.55 +/− 0.18 to 0.42 
+/− 0.15; p < 0.01) and the mean rate of pressure rise (dP/
dt) during isovolumetric contraction (804 +/− 216 to 951 
+/− 282 mmHg/s; p < 0.05) [80].
Patients with Severe Ventricular Dysfunction (<40%)
The therapeutic approach for patients with significant 
DCM has been studied less profoundly and contemporary 
guidelines recommend all drugs used for HF treatment [12, 
15, 81]. 
Although in adult HF, the use of BBs is obligatory in de-
clining of ventricular function, the same evidence in chil-
dren is absent. Last years, some retrospective and non-ran-
domized prospective studies have confirmed the beneficial 
effect of BB therapy in patients with DMD [51, 79, 82-84], 
while in some others this positive effect was not detected 
[85, 86]. Although most of the studies are retrospective and 
included different ages, BB in addition to ACEi demonstrat-
ed to improve 5-year and 7-year survival rates [84], and also 
ventricular function [82]. These contradictory conclusions 
have provided to the variable and frequently insufficient be-
ginning of BB in DMD. However, BB are usually combined 
with ACEi/ARB when a sufficient change in heart function 
is not assessed with basic therapy.
Moreover, in DMD, this therapy is often designated for 
the appearance of autonomic dysfunction and the following 
predilection to arrhythmias [87]. In the contemporary liter-
ature the most frequently used drugs are: carvedilol (0.01–
0.02 mg/kg) administered twice daily and slowly increased 
to a dose of 0.5–1 mg/kg [51,80,82,83,85], metoprolol (1 to 
2 mg/kg/day) [51, 86] and bisoprolol (3–4 mg per day) [84].
In some studies, combined therapy with ACEi/BBs has 
demonstrated to be better to single ACEi [80, 82] in the pre-
vention of major cardiac emergencies [83] and long-term 
survival [84].
End-Stage of DMD DCM
It was recently demonstrated the utility of the HR re-
duction approach achieved with BBs and ivabradine (2.5 
mg twice daily increasing until 15 mg daily every two weeks 
when HR was still above 70 bpm and LVEF < 40%) in the 
decrease of the long-term trend of acute adverse effects in 
DMD patients with advanced heart implication [88]. Previ-
ously, ivabradine demonstrated the effectiveness in HR re-
ducing and LV EF improving in a multicenter, randomized, 
placebo-controlled trial in children with DCM and HF 
symptoms [89].MRAs, spironolactone, and eplerenone are 
recommended in all symptomatic patients (despite treat-
ment with an ACE-I and BB) with HF and LV EF ≤ 35%, 
to decrease death and hospitalization conform to Ameri-
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can and European Guidelines for the management of HF in 
adults [75,  90].
Shortly a new mineralocorticoid receptor antagonist 
(MRA) called vamorolone, will be able to imitate the anti- 
inflammatory impact of glucocorticoids, presumably 
could be a real alternative to both “old MRAs” and “glu-
cocorticoids” in the DMD therapy [91]. To date, there are 
no clinical studies about the use of MRAs in an advanced 
stage of DCM in DMD patients. Despite this, eplerenone 
or spironolactone are used in these patients, at the cardi-
ologist’s decision, in combination therapy with ACEi and 
BB, till they do not manifest hyperkalemia or renal insuf-
ficiency.
Sacubitril/valsartan, the first-in-class angiotensin recep-
tor neprilysin inhibitor (ARNI) has recently been approved 
by the Food and Drugs Administration for the treatment 
of children with symptomatic HF and systemic LV systolic 
dysfunction, that was based on the reduction in the NT-
proBNP levels in sacubitril/valsartan groups compared to 
enalapril one after 12 weeks of treatment in PANORAMA-
HF trial [92]. 
Advanced Cardiac Therapies
Heart Transplant and Mechanical Assist Device
A potential therapy for end-stage HF in these patients is 
the use of a left ventricle assist device (LVAD) as destination 
therapy (DT) [93, 94]. LVAD treatment significantly created 
a reverse ventricular improvement within various mecha-
nisms: reducing ventricular volume, LV mass, hypertrophy, 
and improving its function [95-101]. The use of mechanical 
circulatory support in DMD was described in several case 
reports and small series [102-107DMD Target Therapy
Glucocorticoid therapy has been the standard for pa-
tients with DMD. Deflazacort and prednisone are the most 
recommended steroids. Their introduction changed the 
natural history of the disease, increasing the ambulation 
period, preventing cardiorespiratory insufficiency, and en-
hancing life-expectancy [16, 44]. 
The curative strategies for DMD have focused on replac-
ing dystrophin expression or moderating the processes of 
dystrophin deficiency.
The strategies embraced for dystrophin protein resto-
ration are the following: nonsense readthrough, antisense 
oligonucleotides for exon skipping, and gene therapy. In-
flammation inhibiting, reducing fibrosis, promoting muscle 
regeneration, and mitochondrial function facilitating are 
used to mitigate the dystrophic processes.
This translational investigation has managed the ac-
ceptance of the first target therapies for DMD. Ataluren 
(Translarna™, PTC Therapy) is the first licensed drug for 
DMD in Europe. Ataluren is an oral molecule that connects 
ribosomal RNA subunits and lets ribosomal read through 
of mRNA including a premature stop codon. It is recom-
mended for the therapy of DMD with a nonsense mutation 
in the dystrophin gene.
Recent FDA approved AONs targeting exon 51 (etep-
lirsen) and 53 (golodirsen) for DMD treatment [87].
Conclusions
Information about dystrophinopathies including DMD 
has been rapidly increasing since the initial study by Guil-
laume Duchenne. It is necessary to recognize that these pa-
tients, mostly teenagers and young people, need to be suf-
ficiently managed with the best perspectives, and not with 
conformism and fatality, which in general quickly condemn 
patients with rare diseases, particularly with poor life-ex-
pectancy prognosis. In a careful but positive way, cardiolo-
gists should be mindful of recent studies to implement the 
best available follow-up and management.
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